Results 301 to 310 of about 114,065 (338)
Some of the next articles are maybe not open access.
Transient leukaemia cutis in chronic lymphocytic leukaemia
Clinical and Experimental Dermatology, 1997Leukaemia cutis arises from cutaneous infiltration by neoplastic leukocytes or their precursors. Recent evidence suggests that this sign does not necessarily herald a poor prognosis. We describe a 72-year-old woman with B-cell chronic lymphatic leukaemia who developed a papular eruption of her breast at the site of a recent herpetic eruption. Histology
S H, Wakelin +3 more
openaire +3 more sources
Blood reviews, 2018
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a leading cause of morbidity and mortality. Recently there has been a paradigm shift from the use of chemo-immunotherapies to agents targeting specific B-lymphocyte pathways.
B. Teh +4 more
semanticscholar +1 more source
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a leading cause of morbidity and mortality. Recently there has been a paradigm shift from the use of chemo-immunotherapies to agents targeting specific B-lymphocyte pathways.
B. Teh +4 more
semanticscholar +1 more source
Leukaemia cutis in Chronic CD8+ T Lymphocytic Leukaemia
Dermatology, 1996A 66-year-old woman with CD8+ chronic lymphocytic leukaemia developed multiple indurated erythema or plaques. A skin biopsy specimen showed dense infiltration of leukaemia cells in the dermis and subcutaneous tissue. Most of the infiltrating cells were CD8 + cells.
H, Kishimoto +3 more
openaire +2 more sources
The Lancet Oncology, 2018
BACKGROUND Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia.
P. Cramer +20 more
semanticscholar +1 more source
BACKGROUND Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia.
P. Cramer +20 more
semanticscholar +1 more source
Coexistent Hairy Cell Leukaemia and Chronic Lymphocytic Leukaemia
Leukemia & Lymphoma, 1998Chronic lymphocytic leukaemia (CLL) and hairy cell leukaemia (HCL) are chronic B-cell lymphoproliferative disorders (B-LPDs) with distinct clinical, morphological and immunocytochemical features. Transformation of CLL into other B-LPDs (prolymphocytic leukaemia (PLL) and large cell lymphoma) is a well recognised phenomenon.
S A, Brown +3 more
openaire +2 more sources
Chronic Lymphocytic Leukaemia Associated with Acute Myelomonocytic Leukaemia
British Journal of Haematology, 1973Summary. An elderly male, with no previous medical history of note, presented with haematological changes of chronic lymphocytic leukaemia combined with acute myelomonocytic leukaemia. This patient had never received cytotoxic drugs or radiotherapy.
P D, Roberts, P M, Forster
openaire +2 more sources
Chronic lymphocytic leukaemia.
British journal of hospital medicine, 1992Chronic lymphocytic leukaemia is the commonest of the leukaemias and occurs most often in the elderly. The identification of presenting features that correlate adversely or favourably with survival has allowed the rational development of new treatment strategies.
T D, Karmiris +2 more
openaire +1 more source
Therapy of chronic lymphocytic leukaemia
Best Practice & Research Clinical Haematology, 2010Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence therapeutic decisions. Moreover, fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab,
openaire +2 more sources